A Phase 2 Study to Evaluate the Efficacy of the Combination of Cemiplimab and Cetuximab Prior to Salvage Surgery in Patients With Locally Recurrent (Stage 3-5) OCSCC

To learn if giving cemiplimab and cetuximab before salvage surgery can help to control recurrent OCSCC.

Start Date29 Nov 2024

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

NCT06490913 / Not yet recruitingPhase 2IIT

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes：a Phase II Single-arm Study

The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.

Start Date01 Nov 2024

Sponsor / Collaborator

Fujian Cancer Hospital

NCT06369259 / Not yet recruitingPhase 2IIT

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

To learn if avutometinib in combination with defactinib and cetuximab can help to control unresectable, anti-EGFR-refractory, advanced colorectal cancer.

Start Date31 Oct 2024

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

100 Clinical Results associated with Cetuximab

100 Translational Medicine associated with Cetuximab

100 Patents (Medical) associated with Cetuximab

7,395

Literatures (Medical) associated with Cetuximab

01 Dec 2024·Cellular and molecular life sciences : CMLS

Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer

Article

Author: Jones, Vivian Truong ; Singh, Bhuminder ; Bogatcheva, Galina ; Damalanka, Vishnu C ; Janetka, James W ; Coffey, Robert J ; Joshi, Neeraj ; Liu, Qi ; Harmych, Sarah J ; Sharma, Vineeta ; Ayers, Gregory D ; Roland, Joseph T ; Higginbotham, James N ; Ramirez, Marisol A ; Wahoski, Claudia C ; Graves-Deal, Ramona ; Cao, Zheng ; Irudayam, Maria Johnson

Abstract:

Although amplifications and mutations in receptor tyrosine kinases (RTKs) act as bona fide oncogenes, in most cancers, RTKs maintain moderate expression and remain wild-type. Consequently, cognate ligands control many facets of tumorigenesis, including resistance to anti-RTK therapies. Herein, we show that the ligands for the RTKs MET and RON, HGF and HGFL, respectively, are synthesized as inactive precursors that are activated by cellular proteases. Our newly generated HGF/HGFL protease inhibitors could overcome both de novo and acquired cetuximab resistance in colorectal cancer (CRC). Conversely, HGF overexpression was necessary and sufficient to induce cetuximab resistance and loss of polarity. Moreover, HGF-induced cetuximab resistance could be overcome by the downstream MET inhibitor, crizotinib, and upstream protease inhibitors. Additionally, HAI-1, an endogenous inhibitor of HGF proteases, (i) was downregulated in CRC, (ii) exhibited increased genomic methylation that correlated with poor prognosis, (iii) HAI-1 expression correlated with cetuximab response in a panel of cancer cell lines, and (iv) exogenous addition of recombinant HAI-1 overcame cetuximab resistance in CC-HGF cells. Thus, we describe a targetable, autocrine HAI-1/Protease/HGF/MET axis in cetuximab resistance in CRC.

01 Mar 2024·Cancer

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Article

Author: Daletzakis, Antonios ; Smit, Egbert F ; de Langen, Adrianus J ; Hendriks, Lizza E L ; van Veggel, Bianca A M H ; van der Wekken, Anthonie J ; Paats, Marthe S ; Hashemi, Sayed M S ; van den Broek, Daan ; Bosch, Linda J W ; Monkhorst, Kim

Abstract:

Background:

Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations are the third most common EGFR mutations in patients with non–small cell lung cancer (NSCLC) and are associated with primary resistance to EGFR tyrosine kinase inhibitors (TKIs). There is evidence of activity of combining EGFR TKIs with monoclonal antibodies. This study reports on the efficacy and safety of afatinib in combination with cetuximab.

Methods:

In this single‐arm phase 2 trial, patients with advanced NSCLC harboring an EGFR ex20ins mutation were treated with afatinib 40 mg once daily in combination with cetuximab 500 mg/m2 every 2 weeks. The primary end point was disease control rate (DCR) at 18 weeks of treatment.

Results:

Thirty‐seven patients started treatment, with a median age of 65 years (range, 40–80 years), 78% female, and 95% White. The study achieved its primary end point with a DCR of 54% at 18 weeks, an overall response rate (ORR) of 43%, and a 32% confirmed ORR. Best responses were partial (n = 16), stable (n = 16), progressive disease (n = 2), or not evaluable (n = 3). Median progression‐free survival was 5.5 months (95% CI, 3.7–8.3 months) and median overall survival was 16.8 months (95% CI, 10.7–25.8 months). The most common treatment‐related adverse events (TRAEs) were diarrhea (70%), rash (65%), dry skin (59%), paronychia (54%), and erythema (43%). Grade 3 TRAEs were reported in 54% of all patients.

Conclusions:

Combination treatment with afatinib and cetuximab demonstrated antitumor activity with a DCR of 54% at 18 weeks and a 32% confirmed ORR. Toxicity was significant, although manageable, after dose reduction.

01 Feb 2024·Anti-cancer drugs

Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel KRAS P34R

Article

Author: Chen, Ruizhi ; Yang, Dongmei ; Wang, Boquan ; Xu, Huiting ; Liu, Yang

Cetuximab [the epidermal growth factor receptor (EGFR)-targeting mAb] improves clinical outcomes when added to standard chemotherapy used in the treatment of metastatic colorectal cancer. Patients with hotspot mutations in Kirsten rat sarcoma viral oncogene (KRAS) mutation in exon 2 were not recommended to be treated with cetuximab. However, there is still a lack of clinical data for those unreported non-hotspot KRAS mutations in exon 2 and their response to cetuximab. In this study, we reported a 35-year-old woman who was diagnosed with stage IVA CRC with liver metastases. An exceptionally uncommon KRAS P34R mutation in KRAS exon 2 was detected in tumor specimens by next-generation sequencing. This patient obtained limited benefit from first-line chemotherapy and did not respond to cetuximab in the second-line course. In the third-line course, the patient also did not respond to the combination treatment of furaquitinib and cindilimab. The patient died 8 months after treatment initiation. In this study, we found amplification of the rare oncogenic KRAS P34R was not only associated with an aggressive phenotype, but also supported cancer resistance to cetuximab, chemotherapy, and immunotherapy.

368

News (Medical) associated with Cetuximab

11 Jul 2024

·www.biospace.com

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment Durability of responses tracks well and over 50% of patients received treatment for at least six months Combination continues to have a favourable safety pro no new safety signals observed Based on encouraging results and high unmet medical need, the path forward will be discussed with regulatory agencies Company to host webcast today at 9am AEST (7pm ET, 11 July), details below SYDNEY, AUSTRALIA, July 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression. The updated efficacy and safety data was presented by Dr. Robert Metcalf during an oral presentation at the ESMO Virtual Plenary session at 18:30-19:30 CEST on 11 July 2024. Results The investigational immuno-oncology (IO) combination utilising efti and KEYTRUDA achieved an objective response rate (ORR) of 35.5% (11 of 31 evaluable patients) and a disease control rate (DCR) of 58.1%, according to RECIST 1.1, in 1L HNSCC patients whose tumours do not express PD-L1 (Combined Positive Score [CPS] <1). These results are among the highest recorded for a chemotherapy-free approach in negative PD-L1 patients and compare favourably to a historical control of 5.4% ORR and 32.4% DCR from anti-PD-1 monotherapy.1 Additionally, the IO combination attained a high complete response rate of 9.7% (3 of 31 patients), which compares favourably to a historical control of 0% from anti-PD-1 monotherapy in 1L HNSCC patients with a CPS <1.2 Notably, one patient with early progressive disease according to RECIST 1.1 has evolved into a confirmed partial responder who remains on therapy after 14 months, resulting in a 38.7% ORR for the IO-combination, according to iRECIST. Robert Metcalf, MD, PhD, The Christie NHS Foundation Trust, Manchester, U.K., stated, "The high response rate from this novel immunotherapy combination is well above other treatment approaches without chemotherapy. It matches historical response rates from chemotherapy-based treatments but without the associated toxicities. This is really significant for patients with head and neck squamous cell carcinomas who have a CPS less than one and for whom chemotherapy is the current first line treatment. Achieving complete responses in this group bodes well for this immunotherapy combination's future potential, especially given the positive trend in response durability. The clinically meaningful response rate and high unmet medical need warrant further investigation of eftilagimod plus pembrolizumab in this patient population." Durability of Responses and Favourable Safety Durability of responses is tracking well as has been seen in other clinical trials when efti is combined with KEYTRUDA. Over 50% of patients in Cohort B received treatment for at least six months with three additional patients nearing this threshold at the time of data cut off (11 March 2024). The combination also continues to have a favourable safety pro no new safety signals observed. This new data adds to the body of evidence that efti’s novel activation of antigen-presenting cells provides a strong boost to the immune system, enhancing the potential of immune checkpoint inhibitors such as KEYTRUDA. Importantly, as the only MHC Class II agonist in clinical development today, efti is generating a broad anti-cancer immune response in a unique and safe manner across all levels of PD-L1 expression, especially in patients with negative expression (CPS <1). Next Steps Based on the encouraging efficacy and high unmet medical need, Immutep will discuss the path forward with regulatory agencies. Efti has received FDA Fast Track designation in 1L HNSCC regardless of PD-L1 expression. The prevalence for CPS <1, CPS 1-19, and CPS >20 PD-L1 expression levels are approximately 20%, 30%, and 50% of the HNSCC patient population, respectively.3 Webcast Details Immutep will host a webcast to discuss the clinical data. A replay of the webcast will be available under the Events section of Immutep’s website after the event. Date/Time: Friday, July 12, at 9am AEST (7pm ET July 11) Register: Link to register for webcast Questions: Investors are invited to submit questions in advance via immutep@morrowsodali.com KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. About the TACTI-003 Trial The TACTI-003 (KEYNOTE-PNC-34) trial is an ongoing Phase IIb study evaluating eftilagimod alfa (efti), Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist, in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The randomized Cohort A portion of the study is evaluating efti in combination with pembrolizumab as compared to pembrolizumab monotherapy in patients with PD-L1 positive (Combined Positive Score [CPS] ≥1) tumours, whereas Cohort B is evaluating efti in combination with pembrolizumab in patients with PD-L1 negative tumours. The primary endpoint of the study is Overall Response Rate of evaluable patients according to RECIST 1.1. Secondary endpoints include Overall Survival, Overall Response Rate according to iRECIST, Progression Free Survival, and Duration of Response. For more information about the Phase IIb trial, visit clinicaltrials.gov (NCT04811027). About Eftilagimod Alfa (Efti) Efti is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist that stimulates both innate and adaptive immunity for the treatment of cancer. As a first-in-class antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex) Class II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like IFN-ƴ and CXCL10 that further boost the immune system’s ability to fight cancer. Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety pro various combinations, including with anti-PD-[L]1 immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA). About Immutep Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit . Australian Investors/Media: Catherine Strong, Morrow Sodali +61 (0)406 759 268; c.strong@morrowsodali.com U.S. Media: Chris Basta, VP, Investor Relations and Corporate Communications +1 (631) 318 4000; chris.basta@immutep.com 1,2 Burtness, B. et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. Journal of Clinical Oncology 2022 40:21, 2321-2332. Note, the 5.4% ORR and 32.4% DCR are calculated from the 37 evaluable patients with CPS <1. 3 Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study The Lancet Volume 394, Issue 10212, P1915-1928, Nov 2019.

Clinical ResultPhase 2ImmunotherapyFast TrackPhase 3

09 Jul 2024

·www.biospace.com

Global KRAS Inhibitors Drug Sales Is Expected To Surpass USD 600 Million By 2030

At Present Only 2 Drugs Are Approved In Market With More Than 90 Drugs In Clinical Trials KRAS-targeted therapies have emerges as a groundbreaking opportunity in oncology drug development, addressing a long-standing challenge in cancer treatment. after decades of being considered “undruggable”, the KRAS protein has finally succumbed to therapeutic intervention, opening a substantial commercial opportunity for pharmaceutical companies. The market for these therapies has shown a remarkable growth since the first approval in 2021, exceeding US$ 300 million in 2023, driven by high unmet medical needs and the prevalence of KRAS mutations in various cancers. Download KRAS Inhibitors Commercial & Clinical Development Insight As of July 2024, two KRAS targeted therapies have received approval. The first, Lumakras (sotorasib) from Amgen, was approved in May 2021 for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. The second, Krazati (adagrasib) from Mirati Therapeutics, received approval in December 2022, also for NSCLC patients with KRAS G12C mutations. Furthermore, in June 2024, it received an accelerated approval for the treatment of adult patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) in combination with Erbitux (cetuximab). These approvals have validated the KRAS-targeting approach and paved the way for further development in this space. Currently undergoing late-stage clinical trials and possibly the next in line for regulatory clearance are D-1553 (Garsorasib) from Chia Tai Tianqing Pharmaceutical, Glecirasib (JAB-21822) from Jacobio Pharma, and MK-1084 from Merck, among others. This shows the robust involvement of pharmaceutical companies around the world working to improve treatment outcomes for patients with KRAS-mutated cancers. In addition, certain regional drug regulatory agencies have accepted the New Drug Application (NDA) for Glecirasib and Garsorasib, as well as a few others. These drugs are anticipated to be approved and launched within the next year. The commercial opportunity for KRAS-targeted therapies is significant, underpinned by several key factors. KRAS mutations occur in approximately 25% of all cancers, with particularly high frequencies in pancreatic cancer, colorectal cancer and lung cancer. This translates into a substantial patient population, providing a large addressable market. While current approved therapies majorly focus on the G12C mutations, such as G12V and G12D. Success in these areas would significantly expand the market potential. Combination therapies represent another avenue for growth. KRAS inhibitors are being studies in combination with targeted therapies, immunotherapies, and standard-of-care treatments. For instance, Sidney Kimmel Comprehensive Cancer Center is conducting a Phase 1 clinical trial assessing the combination of a KRAS-targeted vaccine with Nivolumab (anti-PD-1) and Ipilimumab (anti-CTLA-4) for patients with NSCLC. Successful combinations could lead to improved efficacy, expanded indications, and increased market share. Additionally, the global potential is considerable. Initial approvals have focused on the US market, but global expansion presents significant opportunities, particularly in Europe and Asia. As precision medicines addressing a critical unmet need, KRAS-targeted therapies command premium pricing. For example, Lumakras is priced at approximately US$ 22,245 per month in the US. This pricing strategy, combined with the potential for label expansion to other KRAS-mutated cancers, further enhances the commercial prospects of these therapies. The rapid market growth and intense research activity in this field suggests that KRAS-targeted therapies will continue to be a major focus of for pharmaceutical companies and investors. As more data emerges from ongoing clinical trials and potentially new approvals are granted, the market is expected to expand significantly in the coming years, possibly reaching billions of dollars annually within the next decade.

Drug ApprovalPhase 1VaccineAccelerated Approval

03 Jul 2024

·www.pharmaceutical-technology.com

AbbVie licenses OSE’s chronic inflammation therapy for $48m upfront

OSE-230 is a ChemR23, a G-Protein coupled receptor (GPCR) targeting monoclonal antibody. Image Credit: Poetra.RH / Shutterstock. AbbVie has signed a partnership and licensing agreement with OSE Immunotherapeutics for the latter’s monoclonal antibody OSE-230 in a deal worth up to $713m. OSE-230 is a monoclonal antibody that targets ChemR23, a G-Protein coupled receptor (GPCR). The therapy can potentially resolve chronic inflammation and modulate the function of macrophages and neutrophils. It is currently in preclinical development. Following the news, OSE’s stock was up by more than 55% in trading today. The French pharmaceutical company’s market cap stands at $111.2m. Under the collaboration agreement, AbbVie will pay $48m in upfront payment for the exclusive global licence of the therapy. OSE will also be in line to receive up to $665m in milestone-based payments along with tiered royalties on net sales. OSE has a pipeline of multiple monoclonal antibody candidates that it is developing in collaboration with other pharmaceutical companies. The company is developing two signal regulatory protein α (SIRPα) targeting monoclonal antibodies—BI 765063/ OSE-172 and BI 770371—in collaboration with Boehringer Ingelheim. BI 765063 is being evaluated as a combination therapy with different cancer therapies such as Boehringer’s ezabenlimab, BI 836880, chemotherapy, and Eli Lilly’s Erbitux (cetuximab) in a Phase I trial (NCT05249426). BI 770371 is being evaluated as a monotherapy and in combination with a PD1 inhibitor, BI 754091, in an international Phase I dose escalation and expansion trial (NCT05327946) in patients with solid tumours. OSE is also developing an anti-CD28 selective monoclonal antibody FR104/VEL-101 in partnership with Denmark-based Veloxis Pharmaceuticals. It is being researched as a treatment to help prevent organ rejection in people who have had a kidney transplant. In February 2022, the therapy received a fast track designation by the FDA for prophylaxis against transplant rejection. Veloxis is planning Phase II trials for the subcutaneous therapy. AbbVie has also made recent investments related to antibody therapies. In December 2023, it partnered with BigHat Biosciences to identify and develop antibody therapies in oncology and neuroscience indications. On a larger scale, in November 2023, AbbVie announced a $10.1bn ImmunoGen acquisition deal. The antibody-drug conjugate (ADC) Elahere (mirvetuximab soravtansine-gynx) was a central part of the deal. The therapy was granted priority review by the US Food and Drug Administration with a Prescription Drug User Fee Act (PDUFA) action date of 5 April 2024.

Phase 1License out/inPriority ReviewFast TrackADC

100 Deals associated with Cetuximab

External Link

KEGG	Wiki	ATC	Drug Bank
D03455	Cetuximab	L01XC06	DB00002

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
RAS Wild Type Colorectal Cancer	JP	Merck Biopharma Co., Ltd.	01 Dec 2012
Head and Neck Neoplasms	US	Eli Lilly & Co.	01 Mar 2006
Metastatic Colorectal Carcinoma	EU	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	IS	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	LI	Merck Europe BV	29 Jun 2004
Metastatic Colorectal Carcinoma	NO	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	EU	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	IS	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	LI	Merck Europe BV	29 Jun 2004
Squamous Cell Carcinoma of Head and Neck	NO	Merck Europe BV	29 Jun 2004
Colorectal Cancer	CH	Merck & Co., Inc.	01 Dec 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	CN	Boehringer Ingelheim Pharma GmbH & Co., KG	22 Jul 2015
Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	CN	Merck KGaA	22 Jul 2015
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	CN	Boehringer Ingelheim Pharma GmbH & Co., KG	22 Jul 2015
Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 3	CN	Merck KGaA	22 Jul 2015
Locally Advanced Head and Neck Squamous Cell Carcinoma	Phase 3	CN	Merck KGaA	01 Feb 2009
Non-Small Cell Lung Cancer	Phase 3	DE	Merck KGaA	01 Jan 2009
Advanced Gastric Adenocarcinoma	Phase 3	CN	Merck KGaA	01 Jun 2008
Advanced Gastric Adenocarcinoma	Phase 3	JP	Merck KGaA	01 Jun 2008
Advanced Gastric Adenocarcinoma	Phase 3	AR	Merck KGaA	01 Jun 2008
Advanced Gastric Adenocarcinoma	Phase 3	AU	Merck KGaA	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02515734 (DEEPER, ESMO_GI2024) Manual	Phase 2	Colorectal Cancer First line BRAF Mutation	74	m-FOLFOXIRI plus cetuximab (In right-sided pts)	alkqzymyar(ckkjirfiap) = penmygmgre vgilizkxga (qxezimffyl ) View more	Positive	29 Jun 2024
NCT02515734 (DEEPER, ESMO_GI2024) Manual	Phase 2	Colorectal Cancer First line BRAF Mutation	74	m-FOLFOXIRI plus bevacizumab (In right-sided pts)	alkqzymyar(ckkjirfiap) = gnvisfxvaz vgilizkxga (qxezimffyl ) View more	Positive	29 Jun 2024
NCT00433927 (FIRE-3, ASCO2024) Manual	Phase 3	RAS mutant Colorectal Cancer First line RAS Mutation (Activating) \| BRAF	224	FOLFIRI plus cetuximab (RAS mut)	dednpqghxc(ktegkpigwh) = ahuayjikfk hqddkwtbmg (zekhuadrhx ) View more	Negative	24 May 2024
NCT00433927 (FIRE-3, ASCO2024) Manual	Phase 3		224	FOLFIRI plus bevacizumab (RAS mut)	dednpqghxc(ktegkpigwh) = ticcotilat hqddkwtbmg (zekhuadrhx ) View more	Negative	24 May 2024
NCT05167409 (phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P), ASCO2024)	Phase 2	Metastatic Microsatellite Stable Colorectal Carcinoma	16	Evorpacept (E) 15 mg/kg	wbfhdnmoll(wypfhwaxbk) = zxsnugyvgh dnnarhtovw (fsvhictdur, 0.2 - 30.2) View more	Negative	24 May 2024
ERMES study (ASCO2024)	Phase 3	RAS/BRAF Wild Type Colorectal Cancer Maintenance RAS \| BRAF	139	FOLFIRI/Cetuximab	wyelmkavpf(cpvcvvdnds) = gsebkqobvq nsidjpvqyh (marymakgkl )	Negative	24 May 2024
INTERLINK (ASCO2024)	Not Applicable	Recurrent Squamous Cell Carcinoma of the Head and Neck anti-PD1 \| anti-EGFR	103	Cetuximab <3 months after IO	hakrmjptol(rgnvxmgktf) = wyexhrjqxc qkzyrpfknz (iorsnnmlgt ) View more	Positive	24 May 2024
INTERLINK (ASCO2024)	Not Applicable		103	Cetuximab >3 months after IO	hakrmjptol(rgnvxmgktf) = fmfhaosrnz qkzyrpfknz (iorsnnmlgt ) View more	Positive	24 May 2024
KRYSTAL-1 (Literature) Manual	Phase 1/2	Metastatic Colorectal Carcinoma KRAS G12C	94	Adagrasib plus Cetuximab	wobkxuwjoo(yhyknzrfzv) = mehtpeugjo jsfexlgnne (khocgghqyj ) View more	Positive	08 Apr 2024
NCT04872634 (Pubmed)	Phase 1/2	Non-Small Cell Lung Cancer EGFR-mutated	12	SNK01 + cytotoxic chemotherapy	jyecpgtesg(lmnaqqnriz) = qtyxceyuor frduopmbhw (ufohlpwlct ) View more	-	27 Mar 2024
NCT04474470 (ESMO_TAT2024) Manual	Phase 1/2	Squamous Cell Carcinoma of Head and Neck	17	NT219+cetuximab	vnmhcavpaf(vwpwqqdwui) = xukzeqmfhh vwxtpdxwwp (erhjgydcbq ) View more	Positive	26 Feb 2024
ESMO_TAT2024 Manual	Phase 4	Recurrent Squamous Cell Carcinoma of the Head and Neck PD-1 \| PD-L1	157	Cetuximab+Cisplatin+5-fluorouracil	ubtdsfploj(jfqejmpxzd) = gojuzuqyjj mqiwcoyibw (tgoszlkgug ) View more	Positive	26 Feb 2024
ESMO_TAT2024 Manual	Phase 4		157	Nivolumab pluspaclitaxel and cisplatin/carboplatin-based regimen	ubtdsfploj(jfqejmpxzd) = cfqygkgnik mqiwcoyibw (tgoszlkgug ) View more	Positive	26 Feb 2024
NCT01588431 (CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck	3	Cetuximab+Docetaxel+Cisplatin+Bevacizumab	lsajeduckm(phtmtxrbip) = aevgikumuf ijaideliug (xohuuxsyii, ocjozpsgwe - mqvkrobknf) View more	-	14 Feb 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis